Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 15,824 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Product Clear all

Conditions: Kidney Neoplasms, Neoplasm Metastasis
Interventions: PSC 833, vinblastine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Small Cell Lung Cancer
Interventions: APG-1252, Paclitaxel; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Plantation, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Chronic Pain, Fatigue, Substance Use Disorders
Interventions: Not listed
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Small Cell Lung Cancer
Interventions: topotecan/cisplatin, etoposide/cisplatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 66
States / cities: Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more

Conditions: Sickle Cell Disease
Interventions: sodium nitrite injection, usp; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 8 Years to 23 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cystic Fibrosis
Interventions: Placebo, Tobi Podhaler; Drug · Device
Lead sponsor: Mylan Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Miami, Florida • Orlando, Florida • Pensacola, Florida + 4 more

Conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions: Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Drug · Procedure · Biological + 1 more
Lead sponsor: Emory University; Other
Eligibility: 12 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Sepsis, Septicemia, Sepsis Syndrome, Shock, Septic, Community Acquired Pneumonia
Interventions: Not listed
Lead sponsor: National Center for Genome Resources; Other
Eligibility: 6 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: Detroit, Michigan • Durham, North Carolina

Conditions: Brain Tumor Adult
Interventions: DRI cell therapy; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hepatocellular Carcinoma Non-resectable
Interventions: Fluorine-18 fluorocholine; Combination Product
Lead sponsor: Queen's Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Placebo, Pomalidomide, Moxifloxacin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: IUD
Interventions: Menstrual disc with EMLA cream, Cervical cap with EMLA cream; Combination Product
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Myelodysplastic Syndrome
Interventions: Vosaroxin; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Failure
Interventions: LCP-Tacro tablets, Prograf; Drug
Lead sponsor: Veloxis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Major Depressive Disorder
Interventions: Placebo, intermittent theta burst stimulation, intravenous citalopram hydrochloride (CIT), continuous theta burst stimulation; Drug · Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Esophageal Cancer, Gastroesophageal Cancer
Interventions: Oxaliplatin, Irinotecan; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Orange, California

Conditions: HIV/AIDS
Interventions: Albuvirtide, 3BNC117 Antibody; Drug
Lead sponsor: Frontier Biotechnologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Canoga Park, California • San Francisco, California • Hialeah, Florida + 4 more

Conditions: Cystic Fibrosis
Interventions: LUM/IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 34 more

Conditions: Nicotine, Nicotine Vaping, E-cigarette Use
Interventions: Vaping study EC A, Vaping study EC B, Vaping study EC C, Vaping study EC D, Vaping study EC E, Vaping study EC F, Vaping study EC G, Vaping study EC H, Vaping study EC I, Vaping study EC J; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 50 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: To Determine Bioequivalence Under Fed Conditions
Interventions: Lisinopril; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: [14C]PF-05221304; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment
Interventions: No Intervention, donanemab; Other · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 60 Years to 90 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 23
States / cities: Phoenix, Arizona • Irvine, California • Bradenton, Florida + 19 more

Conditions: Infantile Spasms
Interventions: Ganaxolone, Placebo; Drug · Other
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 4 Months to 24 Months
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more

Conditions: Asthma, Copd, Acute Exacerbation of COPD
Interventions: Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction; Device · Other
Lead sponsor: Koronis Biomedical Technologies; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Real-world Momentary Assessment of Kratom Use Accompanied by Product Assays: A Natural-history Study for Interdisciplinary Characterization of Kratom Use and Pharmacology

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests

Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

A Phase 1 QT Study in Healthy Male Subjects

Use of Cervical Cap and Menstrual Disc for Application of Topical Anesthetic Prior to IUD Insertion

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Developing E-liquid Product Standards (Sweet Spot Study)

A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

Inhaler Trainer Efficacy Study